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The World Health Organization recognizes Chagas disease, 
which is caused by the kinetoplastid protozoan Trypanosoma cruzi, 
as “one of the world’s 10 most neglected tropical diseases.”18 Pri-
marily seen in Central and South America, T. cruzi is now recog-
nized as endemic in various areas of the southern United States.5 
Transmission usually occurs through the bite of hematophagous 
triatomine bugs but can also occur through the oral route,5 due to 
blood transfusion4 or organ transplantation,3,8 and through verti-
cal transmission.9
Clinical signs of Chagas vary between the acute and chronic 
phases of disease. During the acute phase, symptoms can include 
swelling at the inoculation site, lymphoadenopathy, fever, my-
algia, and rash. More rare severe acute disease can include me-
ningoencephalitis,12 acute myocarditis, and pericardial effusion.15 
In humans, the chronic phase usually occurs 10 to 30 years after 
the initial infection in untreated patients.13 Symptoms include 
anemia; cardiomyopathy involving cardiac insufficiency, myocar-
ditis, or cardiac arrhythmia; and digestive disease such as mega-
colon and megaesophagus.18
Case Report
History. A 5-y-old, male, research-naïve cynomolgus macaque 
(Macaca fascicularis) was enrolled in a cardiac allograft transplan-
tation study under a protocol approved by the IACUC at the Uni-
versity of Maryland School of Medicine (Baltimore, MD). This 
macaque originated from a facility in the southern United States, 
where he was born, raised, and housed in indoor–outdoor group 
housing. The dam’s origin was Chinese; sire’s identity and origin 
were unknown. The heart donor was a 6-y-old, male cynomolgus 
macaque that was born and raised in China prior to importation 
into the United States; his parents were born and raised in China.
Upon arrival, both macaques underwent standard facility 
quarantine for 13 wk. During quarantine, each animal had a total 
of 6 consecutive negative tuberculosis tests at 2-wk intervals as 
well as 2 consecutive negative examinations for intestinal para-
sites and pathogenic intestinal bacteria (Salmonella spp., Shigella 
spp, Campyolbacter spp., and Yersinia spp.). After week 13, the 
macaques were released from quarantine for use by the inves-
tigator. For the duration of their stay at the School of Medicine, 
the animals were housed indoors and maintained in accordance 
with the Guide for the Care and Use of Laboratory Animals 10 in our 
AAALAC-accredited facility. All procedures were approved by 
the IACUC of the University of Maryland School of Medicine 
(protocol #1013002).
The recipient macaque underwent surgical transplantation of a 
heterotopic cardiac allograft. Both the donor and the recipient ma-
caques received heparin (200 IU/kg) intravenously prior to graft 
removal and implantation. Briefly, the donor heart was harvested 
by transection of the great vessels and by cutting the left atrial 
wall along the entrance of the pulmonary veins. The left atrium 
was closed after creation of an atrial septal defect by fossa ovalis 
resection. The donor heart was implanted into the recipient’s ab-
domen by connecting the donor aorta to the recipient’s infrarenal 
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organ donor, including archived serum, plasma, and snap-frozen 
tissue (colon, kidney, spleen, liver) were sent for testing. All sam-
ples from blood donors and from the organ donor were negative 
for T. cruzi by RT-PCR.
Pathologic findings. Spleen, lymph node and esophageal sam-
ples from the recipient animal were free of noteworthy gross and 
histologic lesions. On necropsy, multiple firm, nodular lung le-
sions were noted that were approximately 0.5 to 1 cm in diameter 
with circumferential erythema. These lesions corresponded to 
focal areas of moderate to severe chronic pneumonia on histo-
pathology. All other tissues were grossly normal on necropsy. 
Mild myeloid hyperplasia of the bone marrow, consistent with a 
mildly regenerative anemia, was present. The liver demonstrated 
evidence of mild chronic hepatitis, cholestasis, and hemosidero-
sis. The colon and skeletal muscle showed histologic inflamma-
tion, presenting with chronic serositis and with chronic myositis 
and cellulitis, respectively. Samples of the native heart had mod-
erate myocarditis with lymphocytic and monocytic infiltrates. 
The most striking finding involved the transplanted heart, which 
demonstrated severe myocarditis and epicarditis with moderate 
fibrosis, and numerous protozoa consistent with T. cruzi in mul-
tiple tissue sections (Figure 2).
A complete profile of blood cell populations is shown in Figure 3. 
WBC, neutrophil, and lymphocyte counts remained quite stable 
throughout the posttransplantation and infection periods. The 
CD4/CD8 ratio decreased, probably as a result of the alloimmune 
response. However, blood eosinophils increased (2- to 3-fold) 
during the weeks after transplantation, suddenly decreased on 
POD 35, and then remained very low until euthanasia.
Discussion
The literature contains several reports of asymptomatic (but se-
rologic or PCR-positive) T. cruzi in NHP. Reports of symptomatic 
clinical disease include sudden death in a chimpanzee (P. trog-
lodytes),6 encephalitis in a Celebes macaque (M. nigra),15 natural 
Chagas infection in baboons,20 and reactivation of T. cruzi after 
experimental infection with SIV.11 What makes the presented case 
unique is that this animal succumbed to T. cruzi after treatment 
with an alternative immunosuppressive regimen in which no 
glucocorticoids or calcineurin inhibitors were used. Specifically, 
costimulation blockade consists of the selective inhibition of re-
ceptor–ligand interactions involved in the activation of T and B 
cells. The CD28–B7 and CD40–CD154 receptor–ligand pairs play 
major roles in the initiation of immune responses, and inhibition 
of one or both of these pathways (by using antibodies or fusion 
proteins) is associated with significantly decreased responses to 
pathogens, vaccines, and transplant antigens.2,16
Although we were unable to determine the source of the dis-
ease, 2 scenarios might explain the occurrence. The most like-
ly case is that the donor animal was the source of the T. cruzi. 
Given that histopathologic changes were present only in the do-
nor heart, the immunomodulation provided by costimulation 
blockade likely reactivated latent disease in the transplanted 
heart, which then shed organisms that were seen on peripheral 
blood smears and ultimately led to widespread Chagas disease. 
The other possibility is that the recipient animal was actually 
previously infected with T. cruzi but was asymptomatic, such that 
immunotherapy led to reactivation of the disease and clinical 
Chagas disease.
aorta and the donor pulmonary artery to the recipient’s infrare-
nal vena cava. The recipient macaque recovered normally from 
surgery and received an immunosuppressive regimen compris-
ing costimulation blockade with monoclonal antibodies specific 
for human CD154 (hu5c8 mouse–human chimeric antibody [re-
combinant], NHP Reagent Resource, Worcester, MA) and human 
CD28 (FR104, monovalent PEGylated Fab antibody antagonist, 
Effimune, Nantes, France).
The recipient macaque was doing well until postoperative day 
(POD) 35, when CBC analysis revealed mild anemia (Table 1). 
Subsequent CBC panels showed progression of the anemia, and 
type-matched whole blood transfusions were started on POD 
47. The macaque was bright and alert at this time. A total of 4 
blood transfusions on POD 47, 49, 50, and 56 were provided for 
clinical support according to the approved IACUC protocol. Af-
ter these 4 blood transfusions, the animal’s anemia showed mild 
regeneration as evidenced by anisocytosis and reticulocytosis 
on blood smears. Throughout this time, the animal was bright 
initially but became progressively lethargic and weak. Because 
the macaque’s weight subsequently dropped below the eutha-
nasia criteria of 20% weight loss, he was euthanized on POD 
64. The transplanted graft had normal function at the time of 
euthanasia. A necropsy was performed, and tissues were sent 
for histopathology.
Hematology and PCR testing. Immune monitoring of the recipi-
ent included standard hematologic and flow cytometric analysis 
of peripheral blood samples at regular intervals. Absolute cell 
counts with differentials were obtained (Antech Diagnostics, Ir-
vine, CA). In addition, blood samples (50 μL) were mixed with 
the fluorescently labeled antibodies CD45–PerCP (clone D058-
1283), CD2–FITC (clone RPA-2.10), CD3–BV450 (clone SP34-2), 
and CD20–PE (clone 2H7; all labeled antibodies were obtained 
from BD Biosciences, San Jose, CA) in specialized tubes (BD Tru-
count, BD Biosciences). The absolute count of each cell population 
was calculated as the number of positive cell events divided by 
the number of bead events and then multiplied by the bead con-
centration. For phenotypic analysis, 50 μL of blood was stained 
with CD3–BV450 (clone SP34-2, BD Biosciences, San Jose, CA), 
CD4–BV500 (clone L200, BD Biosciences, San Jose, CA), or CD8–
PerCP (clone SK1, BD Biosciences Pharmingen, San Diego, CA), 
and the CD4:CD8 ratio of the CD3+ population was calculated. 
All samples were evaluated by flow cytometry (Verse, BD Biosci-
ences), and results were analyzed by using Flowjo (version 0.6; 
Tree Star, Ashland OR).
Because of the macaque’s persistent anemia and our previous 
experience with simian parvovirus as a cause of posttransplanta-
tion anemia,19 POD 50 blood was submitted for RT-PCR testing 
for simian parvovirus (Zoologix, Chatsworth, CA); the assay re-
sults were negative for this virus. In these studies, mild anemia 
is common and routinely addressed with iron dextran injections, 
but this animal’s anemia was persistent and not responsive to 
transfusion. In addition, after the second blood transfusion, the 
reference laboratory measuring CBC values noted few to moder-
ate numbers of trypomastigotes (most closely resembling T. cruzi) 
on blood smears (Figure 1). At this time, whole blood sent for RT-
PCR testing was positive for T, cruzi.
In an attempt to identify the source of the T. cruzi, whole-blood 
samples from all colony animals that were transfusion donors for 
the anemic transplant recipient were tested by RT-PCR (Zoologix) 
for the presence of the organism. In addition, samples from the 
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Table 1. Results of CBC analyses
POD Hgb (g/dL) Hct (%)
WBC 
(× 103 cells/μL)
RBC 
(x 106 cells/mL)
Neutrophils 
(cells/μL)
Lymphocytes 
(cells/μL) 
Eosinophils 
(cells/μL) 
Platelets 
(× 103 cells/μL)
35 9.0 24.4 5.3 3.82 2968 2067 53 849
47 2.3 7.3 4.6 0.96 1380 2898 0 859
50 5.6 17.8 9.0 2.27 3780 4860 180 385
54 5.9 18.7 8.3 2.26 3071 4814 0 451
56 4.5 14.1 11 1.90 — — 0 —
64 5.1 14.4 9.9 1.77 2871 6237 0 903
POD, postoperative day
All CBC results are from ANTECH Diagnostics (Irvine, CA), except for those on POD 56, which were obtained inhouse.
Normal reference ranges: Hgb, 9.6–13.3 g/dL; Hct, 24%–41%; WBC, 4.5–18.3 ×103 cells/μL; RBC, 3.5–6.9 × 106 cells/mL; neutrophils, 4800–12,000 
cells/μL; lymphocytes, 999–10,551 cells/μL; eosinophils, (80–800 cells/μL)
Figure 1. This peripheral blood smear from POD 50 contains trypomas-
tigotes (red arrows), with anisocytosis and polychromasia due to the 
poorly regenerative anemia
Figure 2. Transplanted heart, right ventricle. Clusters of protozoa, con-
sistent with T. cruzi (red arrows), severe myocarditis, and fibrosis are 
present.
Although pharmacologic therapies for T. cruzi infections in 
humans exist, few resources for treatment of NHP are available. 
Medications used to treat humans include benznidazole, which 
has the highest efficacy, and nifurtinox.18 Both of these drugs can 
have serious side effects, are not fully effective, and are only avail-
able through the Centers for Disease Control and Prevention in 
the United States. In humans, these drugs are used only during 
acute infection (which is usually not recognized) or reactivation; 
other than organ transplant in the face of organ failure, there is 
no specific treatment for the end-organ damage caused by infec-
tion. Drug unavailability and humane experimental endpoints 
precluded treatment of this animal after diagnosis. Because treat-
ment is usually prolonged (60 to 90 d) and is most effective dur-
ing acute or reactivated phases, therapy is not a viable option in 
NHP used for research. Finally, the efficacy of treatment against 
T. cruzi has not been validated in the context of immunosuppres-
sion7. Therefore, careful screening is the key to prevent use of 
NHP that may have been infected with this organism.
Routine screening testing should be performed on all NHP en-
tering research facilities when the animals have originated from a 
geographic location where Chagas is known to be endemic. This 
is particularly true of NHP that will be used in cardiac, gastroin-
testinal, or immunosuppressive studies, such as those involving 
transplantation or myelosuppressive irradiation. Testing methods 
for T. cruzi detection include RT-PCR, dipstick assay (ELISA, rap-
id immunochromotographic strip assay), and peripheral blood 
smears. Although PCR testing is typically considered the ‘gold 
standard,’14 even this method can miss animals that have been 
infected with T. cruzi, especially chronically ill animals. In a re-
cent study, 23% of macaques that were IgG ELISA-positive tested 
negative by RT-PCR, and of these animals, 70% had previously 
been positive for T. cruzi by PCR assay.17 Given the inconsistency 
of these tests, multimodal testing by PCR analysis and ELISA and 
multiple testing of quarantined animals may be the most accurate 
method for detecting prior or active infection with this organ-
ism. Because of the associated cost, we recommend this approach 
only for animals from endemic areas and their first-generation 
offspring and when T. cruzi would likely have a significant effect 
on the study to be performed.
Eosinophils play an important role in fighting parasitic in-
fections, when their numbers first increase and then decrease 
due to migration from peripheral blood to the site infected by 
the parasite.13 In the animal we describe here, eosinophil num-
bers were increased during the first weeks after transplantation 
and then decreased abruptly on POD 35. In control transplant 
recipients treated with the same regimen, eosinophil numbers 
either remained stable or typically increased during the weeks 
after transplantation. This increase might reflect the inhibition 
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Figure 3. Hematology and flow cytometric analysis. Solid symbols, T. cruzi-infected recipient; open symbols, average eosinophil counts from 5 control 
transplant recipients treated with the same regimen. Gray arrows indicate blood transfusions. Plt, platelets; NE, neutrophils, MO, monocytes; LY, lym-
phocytes; EO, eosinophils; CD3+, T cells; CD20+, B cells.
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of Th1 responses by costimulation blockade-based immuno-
modulation, allowing ongoing alloimmune responses to favor 
an immune shift toward Th2 responses. Therefore, the initial in-
crease in eosinophils in our macaque may be related to the im-
munosuppression and transplantation events rather than to the 
parasitic infection. However, uninfected control animals did not 
demonstrate a decrease in eosinophil counts (Figure 3, open sym-
bols). Therefore we infer that the dramatic decrease in peripheral 
blood eosinophils might be an early marker of infection with T. 
cruzi (or other parasites), and we therefore recommend initiating 
specific diagnostic tests in response, especially when this obser-
vation is combined with decreased RBC numbers and anemia 
in NHP.
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